6355 related articles for article (PubMed ID: 3142675)
1. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma.
Creagan ET; Loprinzi CL; Ahmann DL; Schaid DJ
Cancer; 1988 Dec; 62(12):2472-4. PubMed ID: 3142675
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
Schiller JH; Storer B; Bittner G; Willson JK; Borden EC
J Interferon Res; 1988 Oct; 8(5):581-9. PubMed ID: 3148669
[TBL] [Abstract][Full Text] [Related]
3. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Itri LM
Cancer; 1986 Dec; 58(12):2576-8. PubMed ID: 3779607
[TBL] [Abstract][Full Text] [Related]
4. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer Treat Rep; 1986 May; 70(5):619-24. PubMed ID: 3518925
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma.
Kowalzick L; Weyer U; Lange P; Breitbart EW
Dermatologica; 1990; 181(4):298-303. PubMed ID: 2127402
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.
Kurzrock R; Rosenblum MG; Quesada JR; Sherwin SA; Itri LM; Gutterman JU
J Clin Oncol; 1986 Nov; 4(11):1677-83. PubMed ID: 3095504
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma.
Creagan ET; Ahmann DL; Green SJ; Long HJ; Frytak S; O'Fallon JR; Itri LM
J Clin Oncol; 1984 Sep; 2(9):1002-5. PubMed ID: 6470751
[TBL] [Abstract][Full Text] [Related]
9. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders.
Creagan ET; Schaid DJ; Ahmann DL; Frytak S
Am J Clin Oncol; 1988 Dec; 11(6):652-9. PubMed ID: 3142248
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma.
Creagan ET; Ahmann DL; Green SJ; Long HJ; Rubin J; Schutt AJ; Dziewanowski ZE
Cancer; 1984 Dec; 54(12):2844-9. PubMed ID: 6498762
[TBL] [Abstract][Full Text] [Related]
12. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
13. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
[TBL] [Abstract][Full Text] [Related]
14. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of recombinant alpha-interferon in malignant melanoma.
Neefe JR; Legha SS; Markowitz A; Salmon S; Meyskens F; Groopman J; Campion M; Evans L
Am J Clin Oncol; 1990 Dec; 13(6):472-6. PubMed ID: 2239801
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .
Legha SS; Papadopoulos NE; Plager C; Ring S; Chawla SP; Evans LM; Benjamin RS
J Clin Oncol; 1987 Aug; 5(8):1240-6. PubMed ID: 3625246
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
18. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
19. Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
Creagan ET; Long HJ; Frytak S; Moertel CG
Cancer; 1988 Jan; 61(1):19-22. PubMed ID: 2825959
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
